Ksilink : from patient to drug
  • PARTNERING
  • PLATFORM
    • Our approach
    • Our technology
    • Our science
  • PIPELINE
  • ABOUT US
    • Our Story
    • Our team
    • Our Scientific Committee
  • CORPORATE INFORMATION
    • News
    • Investors
    • Partners & Advisors
    • Ksilink Association
  • CONTACT US
New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons

New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons

by Ksil20@Nw-wsite | Aug 29, 2025 | Publications, Unclassified

In collaboration with the University of Luxembourg, Ksilink used a patient-derived cellular model for Parkinson’s Disease based on SNCA triplication and isogenic control mDA neurons to identify and rescue multiple phenotypes. Our pilot screen of > 1000 compounds...
We are thrilled to announce the arrival of our new Chief Operating Officer!

We are thrilled to announce the arrival of our new Chief Operating Officer!

by Ksil20@Nw-wsite | Feb 13, 2025 | Short news

Dr Helmut Haning has recently joined the management of Ksilink as COO, complementing the team with a longstanding experience in pharmaceutical drug discovery. He brings to the company a wealth of knowledge and expertise in drug discovery, strategy and operational...
Join Ksilink at BIO Partnering @ JPM Week 2025!

Join Ksilink at BIO Partnering @ JPM Week 2025!

by Ksil20@Nw-wsite | Jan 2, 2025 | Conferences, Short news

We are excited to announce that Mona Boyé, Head of BD & Partnerships, and Johannes Wilbertz, Team Leader Neuroscience, will be attending BIO Partnering @ JPM Week in San Francisco from January 13-16, 2025. This event is a leading gathering for the biotechnology...
Ksilink Advances PMDS Research and Disease Modelling

Ksilink Advances PMDS Research and Disease Modelling

by Ksil20@Nw-wsite | Jun 11, 2024 | Press releases, Publications

Strasbourg, France – Ksilink, together with our collaborators from I-Stem (Paris), has recently published a scientific paper that provides significant insights into Phelan-McDermid syndrome (PMDS), a genetic disorder that presents complex challenges in...
Artificial Intelligence in Mental Health Summit, July 1st and 2nd, Berlin

Artificial Intelligence in Mental Health Summit, July 1st and 2nd, Berlin

by Ksil20@Nw-wsite | May 23, 2024 | Conferences

Join us for a two-day free event examining the role played by artificial intelligence and digital tools in understanding and supporting mental health. Hosted by the environMENTAL EU Project, Deutsches Zentrum für Psychische Gesundheit (DZPG) and EBRAINS, this event...
« Older Entries
Next Entries »

Video: Ksilink x 2CRSI

https://youtu.be/E22bSHpHGBo

Latest Post

  • We are excited about our new collaboration with Oncodesign Presicion Medicine
  • Bio Europe Spring
  • Meet us at Conferences and Partnerings
  • New publication on phenotypic and transcriptomic characterization, and machine learning-based classification of desmin-related cardiomyopathy disease features
  • New publication on morphological map of under- and overexpression of genes in human cells

Categories

  • Conferences
  • Job Posting
  • Press releases
  • Publications
  • Short news
  • Unclassified
  • Video
Ksilink : from patient to drug

16 rue d’Ankara,
67000 Strasbourg
France

  • Our Approach
  • Technology
  • Pipeline
  • Gender Equality
  • Careers
  • Early Career Program
  • Privacy Policy
Contact us

contact@ksilink.com

Follow us on linkedin

2020 © ksilink. All rights reserved - Photo credit: Pierre Pommereau - Video credit: Mehdi Boswingel - Illustration credit: BioRender.com - Designed by Webdesign Consulting - Legal notices

Ksilink
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}